Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on June 1, 2023. The filing details the voting results for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 4, 2023), 136,736,309 shares were outstanding. 112,922,471 shares (82.58%) were represented at the meeting. The following matters were approved:
- Proposal 1 (Election of Directors): All three Class III nominees were elected to serve until the 2026 annual meeting.
- Jennifer Cook: 87,451,911 votes For.
- David Schenkein, M.D.: 87,642,096 votes For.
- Ryan J. Watts, Ph.D.: 103,702,078 votes For.
- Proposal 2 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 112,694,203 votes For.
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation with 98,002,580 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (Jennifer Cook, David Schenkein, and Ryan J. Watts) through the 2026 annual meeting.
- Confirm the engagement of Ernst & Young LLP for the 2023 fiscal year audit.
- Note the high level of shareholder participation (82.58%) and the strong support for the executive compensation advisory vote.